Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GCOM1 combined protein 1 (GCOM1) is a unique, complex gene product resulting from *readthrough transcription across the MYZAP and POLR2M genes* on chromosome 15, generating a protein with domains from both parent loci as well as unique exons[1][3][2]. GCOM1 proteins are expressed predominantly in the **central nervous system** and at the **intercalated disks of cardiomyocytes**, where they participate in **transcription elongation** (by interacting with the RNA polymerase II complex), **cell–cell adhesion** in the heart, and possibly the modulation of NMDA receptor (NMDAR) function in the brain[1][3]. GCOM1 variants that result in loss of function have been directly implicated in **familial dilated and hypertrophic cardiomyopathy**[3]. Experimental evidence suggests a possible role in **neuroprotection** by modulating NMDA receptor–mediated calcium influx, but the exact CNS function is still not fully characterized[1]. No drugs are currently known to target GCOM1 directly, and its major therapeutic potential is as a modulator within protein complexes—especially those relevant to heart and brain pathology. Key evidence: - GCOM1 is the gene product of a complex transcription unit encompassing exons from MYZAP and POLR2M, producing unique proteins not found in either parent gene alone[2][3]. - GCOM1 interacts with cardiac and neuronal proteins, including the NR1 subunit of the NMDA receptor, and is implicated in both cardiac structural integrity and possible neuroprotective pathways[1]. - Homozygous GCOM1 truncating mutations cause familial cardiomyopathy; there are suggested implications for neuropsychiatric and neurodegenerative diseases, but direct clinical links are not fully established[3][1]. No pharmacologic agents are currently known to act on GCOM1 or its protein products[1][3]. Pathogenic GCOM1 variants serve as potential genetic biomarkers in hereditary cardiomyopathy assessment[3].
none known (neither direct pharmacologic agents nor established inhibitors/agonists are documented)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GCOM1 combined protein 1 (GCOM1).